World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
83
Citations
26390
World Ranking
15568
National Ranking
7844

Borje S. Andersson publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Borje S. Andersson sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 588 publications — 70th percentile

70% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Borje S. Andersson D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Borje S. Andersson sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 83 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Borje S. Andersson is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research spans multiple fields with a primary focus on medicine and a significant body of work in biochemistry, genetics, and molecular biology.

The scientist's main subfields of study include hematology, molecular biology, oncology, public health, environmental and occupational health, and genetics. Their research topics cover a range of areas related to blood diseases and cellular therapies.

The following are key research topics addressed in their work:

  • Acute Myeloid Leukemia Research
  • Hematopoietic Stem Cell Transplantation
  • Histone Deacetylase Inhibitors Research
  • Acute Lymphoblastic Leukemia research
  • Chronic Myeloid Leukemia Treatments
  • CAR-T cell therapy research
  • Polyomavirus and related diseases

They have contributed to several notable publications, including the following recent papers:

  • "T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors," 2021, Journal of Hematology & Oncology
  • "Hematopoietic Stem Cell Transplantation for Severe Thalassemia Patients from Haploidentical Donors Using a Novel Conditioning Regimen," 2020, Biology of Blood and Marrow Transplantation
  • "Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation," 2021, Journal of Clinical Oncology
  • "Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy," 2023, Journal of Hematology & Oncology
  • "Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial," 2021, Transplantation and Cellular Therapy

Frequent co-authors collaborating with Borje S. Andersson include:

  • Yago Nieto
  • Uday Popat
  • Elizabeth J. Shpall
  • Chitra Hosing
  • Richard E. Champlin

Their work has appeared consistently in several specialized journals, including:

  • Transplantation and Cellular Therapy
  • Blood
  • Biology of Blood and Marrow Transplantation
  • Bone Marrow Transplantation
  • Journal of Clinical Oncology

Best Publications

  • Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

    Sergio Giralt;Elihu Estey;Maher Albitar;Koen Van Besien

  • Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.

    I F Khouri;M Keating;M Körbling;D Przepiorka

  • Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

    Sergio Giralt;Peter F. Thall;Issa Khouri;Xuemei Wang

  • Allogeneic Blood Stem Cell Transplantation for Refractory Leukemia and Lymphoma: Potential Advantage of Blood Over Marrow Allografts

    M Korbling;D Przepiorka;YO Huh;H Engel

  • Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS

    Marcos de Lima;Daniel Couriel;Peter F. Thall;Xuemei Wang

  • Cord-blood engraftment with ex vivo mesenchymal-cell coculture.

    Marcos J.G. de Lima;Ian McNiece;Simon N. Robinson;Mark Munsell

  • Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

    Marcos De Lima;Athanasios Anagnostopoulos;Mark Munsell;Munir Shahjahan

  • Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease

    D. Przepiorka;N. A. Kernan;C. Ippoliti;E. B. Papadopoulos

  • Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer.

    N T Ueno;G Rondón;N Q Mirza;D K Geisler

  • Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning

    Christopher G. Kanakry;Paul V. O'Donnell;Terry Furlong;Marcos J. De Lima

  • Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes

    J.A Russell;H.T Tran;D Quinlan;A Chaudhry

  • Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial.

    M. de Lima;J. McMannis;A. Gee;K. Komanduri

  • Extracorporeal photochemotherapy for the treatment of steroid resistant chronic GVHD

    Daniel R. Couriel;Chitra Hosing;Rima M Saliba;Elizabeth Shpall

  • Tumor necrosis factor-α blockade for the treatment of acute GVHD

    Daniel Couriel;Rima Saliba;Krystal Hicks;Cindy Ippoliti

  • Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation

    Donna Przepiorka;Donna Przepiorka;Terry L. Smith;Jody Folloder;Issa F Khouri

  • Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.

    Ashwin Kashyap;John Wingard;Pablo Cagnoni;Roy Jones

  • Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect

    K. W. Van Besien;M. De Lima;S. A. Giralt;D. F. Moore

  • Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.

    Borje S. Andersson;Peter F. Thall;Timothy Madden;Daniel Couriel

  • Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia : preliminary results

    I F Khouri;M J Keating;H M Vriesendorp;C L Reading

  • Acute and Chronic Graft-versus-Host Disease after Ablative and Nonmyeloablative Conditioning for Allogeneic Hematopoietic Transplantation

    Daniel R. Couriel;Rima M Saliba;Sergio Giralt;Issa F Khouri

Frequent Co-Authors

Richard E. Champlin
Richard E. Champlin The University of Texas MD Anderson Cancer Center
Elizabeth J. Shpall
Elizabeth J. Shpall The University of Texas MD Anderson Cancer Center
Issa F. Khouri
Issa F. Khouri The University of Texas MD Anderson Cancer Center
Sergio Giralt
Sergio Giralt Memorial Sloan Kettering Cancer Center
Partow Kebriaei
Partow Kebriaei The University of Texas MD Anderson Cancer Center
Peter F. Thall
Peter F. Thall The University of Texas MD Anderson Cancer Center
Donna Przepiorka
Donna Przepiorka US Food and Drug Administration
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Albert B. Deisseroth
Albert B. Deisseroth US Food and Drug Administration
Katayoun Rezvani
Katayoun Rezvani The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring medical careers beyond a traditional M.D. route, several flexible and affordable online degrees can kick-start your journey. For registered nurses looking to advance, finding the rn to bsn cheapest programs online can save both time and money, while boosting your qualifications.

Aspiring nurses without prior experience can consider msn direct entry programs online for a direct and accelerated path into advanced nursing roles. If you’re looking for accessible entry points, there are also options for the easiest rn program to get into, making nursing school more within reach for students from diverse backgrounds.

For those interested in the administrative side of healthcare, pursuing a career in medical billing and coding is another excellent online option. Many accredited programs are available, and you can even find financial aid for medical billing and coding to help offset your education costs.

These alternative pathways can lead to rewarding healthcare careers with different educational timelines and entry requirements, making medical fields more accessible than ever before.

Best Scientists Citing Borje S. Andersson

Trending Scientists

Recently Published Articles